Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells

The development of acquired EGFR‐TKI therapeutic resistance is still a serious clinical problem in the management of lung adenocarcinoma. Peroxisome proliferator activated receptor gamma (PPAR γ) agonists may exhibit anti‐tumor activity by transactivating genes which are closely associated with cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jie, Zhou, Lei‐lei, Ding, Li, Zhang, Xue‐qin, Zhao, Xia, Li, Huizi, Cao, Haixia, Liu, Siwen, Wang, Zhuo, Ma, Rong, Wu, Jianzhong, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943475/
https://www.ncbi.nlm.nih.gov/pubmed/29573196
http://dx.doi.org/10.1002/cam4.1440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943475/
https://www.ncbi.nlm.nih.gov/pubmed/29573196
http://dx.doi.org/10.1002/cam4.1440

Ejemplares similares